{"corpus_id":9362191,"paper_sha":"e1a67fd5e540307550577ea7a071370b075e943f","doi":"10.1086/504810","arxiv_id":null,"pmid":16758414,"pmcid":null,"mag_id":2164001967,"dblp_id":null,"acl_id":null,"title":"Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study.","year":2006,"publication_date":"2006-07-01","venue":"Clinical Infectious Diseases","journal":{"name":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","pages":"\n          25-31\n        ","volume":"43 1"},"journal_issn":null,"journal_title":null,"publication_types":["Study","JournalArticle"],"pubmed_pub_types":["Journal Article","Multicenter Study","Research Support, Non-U.S. Gov't"],"s2_fields_of_study":["Medicine"],"reference_count":21,"citation_count":1154,"influential_citation_count":38,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Adult","mj":false,"ui":"D000328"},{"d":"Aged","mj":false,"ui":"D000368"},{"d":"Antifungal Agents","mj":false,"qs":[{"q":"therapeutic use","mj":true,"ui":"Q000627"}],"ui":"D000935"},{"d":"Candidiasis","mj":false,"qs":[{"q":"drug therapy","mj":true,"ui":"Q000188"},{"q":"mortality","mj":false,"ui":"Q000401"}],"ui":"D002177"},{"d":"Cohort Studies","mj":false,"ui":"D015331"},{"d":"Female","mj":false,"ui":"D005260"},{"d":"Fluconazole","mj":false,"qs":[{"q":"therapeutic use","mj":true,"ui":"Q000627"}],"ui":"D015725"},{"d":"Fungemia","mj":false,"qs":[{"q":"drug therapy","mj":false,"ui":"Q000188"},{"q":"mortality","mj":false,"ui":"Q000401"}],"ui":"D016469"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Length of Stay","mj":false,"ui":"D007902"},{"d":"Male","mj":false,"ui":"D008297"},{"d":"Middle Aged","mj":false,"ui":"D008875"},{"d":"Retrospective Studies","mj":false,"ui":"D012189"},{"d":"Time Factors","mj":false,"ui":"D013997"}],"chemicals":[{"n":"Antifungal Agents","ui":"D000935","reg":"0"},{"n":"Fluconazole","ui":"D015725","reg":"8VZV102JFY"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://academic.oup.com/cid/article-pdf/43/1/25/876682/43-1-25.pdf","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/e1a67fd5e540307550577ea7a071370b075e943f","s2_open_access_license":null,"s2_open_access_status":"BRONZE","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"BACKGROUND: Inadequate antimicrobial treatment is an independent determinant of hospital mortality, and fungal bloodstream infections are among the types of infection with the highest rates of inappropriate initial treatment. Because of significant potential for reducing high mortality rates, we sought to assess the impact of delayed treatment across multiple study sites. The goals our analyses were to establish the frequency and duration of delayed antifungal treatment and to evaluate the relationship between treatment delay and mortality. METHODS: We conducted a retrospective cohort study of patients with candidemia from 4 medical centers who were prescribed fluconazole. Time to initiation of fluconazole therapy was calculated by subtracting the date on which fluconazole therapy was initiated from the culture date of the first blood sample positive for yeast. RESULTS: A total of 230 patients (51% male; mean age +/- standard deviation, 56 +/- 17 years) were identified; 192 of these had not been given prior treatment with fluconazole. Patients most commonly had nonsurgical hospital admission (162 patients [70%]) with a central line catheter (193 [84%]), diabetes (68 [30%]), or cancer (54 [24%]). Candida species causing infection included Candida albicans (129 patients [56%]), Candida glabrata (38 [16%]), Candida parapsilosis (25 [11%]), or Candida tropicalis (15 [7%]). The number of days to the initiation of antifungal treatment was 0 (92 patients [40%]), 1 (38 [17%]), 2 (33 [14%]) or > or = 3 (29 [12%]). Mortality rates were lowest for patients who began therapy on day 0 (14 patients [15%]) followed by patients who began on day 1 (9 [24%]), day 2 (12 [37%]), or day > or = 3 (12 [41%]) (P = .0009 for trend). Multivariate logistic regression was used to calculate independent predictors of mortality, which include increased time until fluconazole initiation (odds ratio, 1.42; P < .05) and Acute Physiology and Chronic Health Evaluation II score (1-point increments; odds ratio, 1.13; P < .05). CONCLUSION: A delay in the initiation of fluconazole therapy in hospitalized patients with candidemia significantly impacted mortality. New methods to avoid delays in appropriate antifungal therapy, such as rapid diagnostic tests or identification of unique risk factors, are needed.","claims":[{"public_id":"cl_d1765199536e536f5188365aa1918a88","status":"active","text":"Longer time to initiation of fluconazole therapy is independently associated with higher mortality in hospitalized patients with candidemia.","confidence":0.98,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_d1765199536e536f5188365aa1918a88"},{"public_id":"cl_ccad0c293acbe0270edcbc6b9f599b0b","status":"active","text":"Mortality increases across treatment-delay categories, from 15% when therapy begins on day 0 to 41% when therapy begins on day 3 or later.","confidence":0.96,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_ccad0c293acbe0270edcbc6b9f599b0b"},{"public_id":"cl_61d5e35ba4713e7f7d276bd466cd20ed","status":"active","text":"The multivariate model identifies increased time until fluconazole initiation and Acute Physiology and Chronic Health Evaluation II score as independent predictors of mortality.","confidence":0.95,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_61d5e35ba4713e7f7d276bd466cd20ed"}],"concepts":[{"public_id":"co_023296e34559f541cbb2dea798043b6b","status":"active","name":"time to initiation of fluconazole therapy","description":"The interval between the first positive blood culture for yeast and the start of fluconazole treatment.","types":["measure"],"aliases":["delay in fluconazole therapy","time until fluconazole initiation"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_023296e34559f541cbb2dea798043b6b"},{"public_id":"co_18b05a991ea44d249dda138758eb18a7","status":"active","name":"fluconazole","description":"An antifungal medication used to treat Candida infections.","types":["drug"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_18b05a991ea44d249dda138758eb18a7"},{"public_id":"co_280d162b47675367a7bdec15373da68f","status":"active","name":"4 medical centers","description":"The four institutions that contributed patients to the cohort.","types":["setting"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_280d162b47675367a7bdec15373da68f"},{"public_id":"co_33dca404d25377db93557727fcc67785","status":"active","name":"retrospective cohort study","description":"A study design that analyzes previously collected patient records over time.","types":["study design"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_33dca404d25377db93557727fcc67785"},{"public_id":"co_3cb8bb15c1c32c814aba90905620d33b","status":"active","name":"Acute Physiology and Chronic Health Evaluation II score","description":"A severity-of-illness score used as a predictor in the mortality analysis.","types":["clinical score"],"aliases":["APACHE II score","APACHE II"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_3cb8bb15c1c32c814aba90905620d33b"},{"public_id":"co_441046524ebfad6831fa113208cbee64","status":"active","name":"rapid diagnostic tests","description":"Tests intended to shorten the time needed to identify infection and guide treatment.","types":["diagnostic method"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_441046524ebfad6831fa113208cbee64"},{"public_id":"co_6568ddaa3b2bb0c70fd7ec0fc4df5e23","status":"active","name":"candidemia","description":"A bloodstream infection caused by Candida species.","types":["condition"],"aliases":["fungal bloodstream infection"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_6568ddaa3b2bb0c70fd7ec0fc4df5e23"},{"public_id":"co_7d73fd961b9d261ceb6fd1d4d606e433","status":"active","name":"day 0 to day 3 or later","description":"Treatment-delay categories defined by the number of days from culture date to fluconazole initiation.","types":["categorical measure"],"aliases":["day 0","day 1","day 2","day 3 or later"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_7d73fd961b9d261ceb6fd1d4d606e433"},{"public_id":"co_bc9815ccc6c7e2489945a9b19e4a4076","status":"active","name":"multivariate logistic regression","description":"A statistical model used to identify independent predictors of mortality.","types":["statistical method"],"aliases":["logistic regression"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_bc9815ccc6c7e2489945a9b19e4a4076"},{"public_id":"co_d01c7ec8e635832530ae1177e9b07cf7","status":"active","name":"mortality","description":"Death outcome assessed in patients with candidemia.","types":["outcome"],"aliases":["hospital mortality"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_d01c7ec8e635832530ae1177e9b07cf7"}],"external_ids":{"DOI":"10.1086/504810","ArXiv":null,"PubMed":16758414,"PubMedCentral":null,"MAG":2164001967,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://academic.oup.com/cid/article-pdf/43/1/25/876682/43-1-25.pdf","landing_url":"https://www.semanticscholar.org/paper/e1a67fd5e540307550577ea7a071370b075e943f","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":null,"status":"BRONZE","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":634565,"paper_uid":"6bf4e336-e4ff-4a0b-9566-c282b92c51c0","canonical_identity":{"paper_id":634565,"paper_uid":"6bf4e336-e4ff-4a0b-9566-c282b92c51c0","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/9362191"}